KeChuang Medical ETF Huaxia (588130) opened up over 1%, aiming for a three-day winning streak

On July 22, the A-share market showed divergence. As of 09:41, the Shanghai Composite Index had a gain of -0.10%, and the ChiNext Index had a gain of -0.46%. The pharmaceutical sector demonstrated strong resilience, with the STAR Market pharmaceutical direction performing particularly well. The Huaxia Science and Technology Innovation Medicine ETF (588130) was active during trading hours, rising by 1.04% with a turnover of 7.1388 million yuan. Looking at its constituent stocks, Junshi Biosciences rose by 3.74%, Zekang Pharmaceutical rose by 3.12%, RemeGen increased by 2.75%, while BeiGene, Baili Tianheng, and Haoyuan Pharmachem also turned red.

The outstanding performance of the pharmaceutical sector recently is underpinned by the continuous deepening of industrial innovation logic. This week, the industry continues to receive multiple positive catalysts. On the policy front, the "15th Five-Year Plan" includes a dedicated chapter supporting innovation; on the earnings front, interim report forecasts from companies like Conba and Allist exceeded expectations; on the BD front, transactions from Dizal, Hansoh, and Innovent have been finalized; coupled with the upcoming ESMO conference, data catalysts are anticipated. In the medium to long term, 2027-2028 marks the starting point for the batch commercialization of innovative drugs overseas. The innovative drug sector will welcome a new valuation system, and looking further ahead, there is expected to be elastic upside potential.

The Huaxia Science and Technology Innovation Medicine ETF (588130) provides a convenient tool for low-threshold one-click exposure to the STAR Market pharmaceutical sector. It tracks the SSE STAR Market Biopharmaceutical Index, where the 20% price limit on the STAR Market offers high elasticity. The index is highly concentrated in three core tracks: chemical pharmaceuticals, medical devices, and biological products, with a combined weight exceeding 91%, helping ordinary investors seize long-term development opportunities in the innovative drug and device sectors. (Off-exchange feeder A: 027142; Feeder C: 027143).